Friday, July 31

Browsing: CGT4255

Treatments

81 A First-in-Human Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients Who Have Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

By NewsCancerJune 7, 20260

BackgroundERBB2-activating alterations and HER2 overexpression are present in a range of cancers, including breast cancer. Current ERBB2-directed therapies are limited…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

Browsing: CGT4255

81 A First-in-Human Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients Who Have Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

Latest Post

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

Subscribe to Updates

What's Hot

Browsing: CGT4255